journal article·2025-05-23

Three-Dimensional Printing of Braille-Integrated Drug-Loaded Materials: Advancing Accessibility for Visually Impaired Patients

Sahil Premprakash Wankhede, Ali Bagheri, Xian Du

ACS Applied Polymer Materials· Volume 7· Issue 10
Publisher page

Abstract

3D printing presents a transformative pathway for personalized medicine, particularly in designing accessible medical devices for individuals with visual impairments. Millions worldwide face significant challenges in managing their healthcare routines due to nonstandardized Braille labeling and inadequately designed devices. This study utilizes digital light processing (DLP)-based 3D printing combined with reversible addition–fragmentation chain transfer (RAFT) polymerization to fabricate high-resolution, Braille-integrated materials tailored for visually impaired patients. Investigations focused on optimizing surface quality, structural integrity, and tactile readability to enhance device accessibility and usability. Comprehensive analyses examined the interplay between photopolymer formulations, mechanical performance, and tactile features. Furthermore, this study assessed the integration of pharmaceutical elements, such as drug loading and release characteristics, to evaluate the potential for multifunctional applications. These findings highlight the challenges and strategies involved in integrating tactile accessibility with biomedical functionality for visually impaired individuals.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Photopolymerization techniques and applications · Interactive and Immersive Displays · Additive Manufacturing and 3D Printing Technologies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Mechanical Engineering

University of Massachusetts Amherst

Center for Personalized Health Monitoring, (CPHM)

Institute for Applied Life Sciences (IALS)

School of Science and Technology

University of New England

Funding

University of Massachusetts

References (61)

Show source-provided references
1. 10.1056/NEJMp150052310.1056/NEJMp1500523 ↗
2. 10.33320/maced.pharm.bull.2022.68.03.14110.33320/maced.pharm.bull.2022.68.03.141 ↗
3. 10.1208/s12249-023-02544-510.1208/s12249-023-02544-5 ↗
4. 10.3390/pharmaceutics1106027410.3390/pharmaceutics11060274 ↗
5. 10.1016/j.ijpharm.2023.12328610.1016/j.ijpharm.2023.123286 ↗
6. 10.1016/j.jconrel.2022.08.02210.1016/j.jconrel.2022.08.022 ↗
7. 10.1016/j.mtla.2023.10170010.1016/j.mtla.2023.101700 ↗
8. 10.1016/j.ejpb.2022.02.01310.1016/j.ejpb.2022.02.013 ↗
9. 10.1021/jacsau.2c0043210.1021/jacsau.2c00432 ↗
10. 10.1080/17425247.2022.212181610.1080/17425247.2022.2121816 ↗
11. 10.1016/j.ijpharm.2023.12319410.1016/j.ijpharm.2023.123194 ↗
12. 10.3390/pharmaceutics1405093110.3390/pharmaceutics14050931 ↗
13. 10.1016/j.jconrel.2020.10.00810.1016/j.jconrel.2020.10.008 ↗
14. 10.3390/pharmaceutics1407131210.3390/pharmaceutics14071312 ↗
15. 10.1016/j.eurpolymj.2023.11224010.1016/j.eurpolymj.2023.112240 ↗
16. Lamprou D. · 202310.1007/978-3-031-26908-0 ↗
17. 10.1088/1758-5090/7/4/04500110.1088/1758-5090/7/4/045001 ↗
18. 10.1016/j.aime.2023.10012510.1016/j.aime.2023.100125 ↗
19. 10.1080/17425247.2022.211294410.1080/17425247.2022.2112944 ↗
20. 10.1016/j.cej.2021.13386110.1016/j.cej.2021.133861 ↗
21. 10.1016/j.addma.2021.10246410.1016/j.addma.2021.102464 ↗
22. 10.3390/polym1405097910.3390/polym14050979 ↗
23. 10.1016/j.ijpharm.2017.09.00310.1016/j.ijpharm.2017.09.003 ↗
24. 10.3390/pharmaceutics1202017210.3390/pharmaceutics12020172 ↗
25. 10.1109/TOH.2024.343358210.1109/TOH.2024.3433582 ↗
26. 10.1016/j.jsps.2020.01.00610.1016/j.jsps.2020.01.006 ↗
27. 10.4103/2045-080X.19961310.4103/2045-080X.199613 ↗
28. 10.1109/ICIoT48696.2020.908953610.1109/ICIoT48696.2020.9089536 ↗
29. 10.1109/ELTICOM50775.2020.923051910.1109/ELTICOM50775.2020.9230519 ↗
30. 10.3390/ph1708101710.3390/ph17081017 ↗
31. 10.1016/j.ijpharm.2024.12459410.1016/j.ijpharm.2024.124594 ↗
32. 10.3390/pharmaceutics1309140110.3390/pharmaceutics13091401 ↗
33. 10.1016/j.ijpharm.2016.03.01610.1016/j.ijpharm.2016.03.016 ↗
34. 10.1016/j.addma.2020.10107110.1016/j.addma.2020.101071 ↗
35. 10.1039/C9PY01419E10.1039/C9PY01419E ↗
36. 10.1021/acsapm.9b0107610.1021/acsapm.9b01076 ↗
37. 10.1021/acsapm.1c0004810.1021/acsapm.1c00048 ↗
38. 10.1002/adfm.20231523810.1002/adfm.202315238 ↗
39. 10.1039/D3LP00252G10.1039/D3LP00252G ↗
40. 10.1007/s11426-024-2422-210.1007/s11426-024-2422-2 ↗
41. 10.1021/acsapm.3c0316410.1021/acsapm.3c03164 ↗
42. 10.1002/asia.20240064810.1002/asia.202400648 ↗
43. 10.1002/anie.20231856410.1002/anie.202318564 ↗
44. 10.1002/anie.20190290010.1002/anie.201902900 ↗
45. 10.1002/advs.20200370110.1002/advs.202003701 ↗
46. 10.1016/j.progpolymsci.2009.01.00110.1016/j.progpolymsci.2009.01.001 ↗
47. 10.1021/acsmacrolett.2c0044810.1021/acsmacrolett.2c00448 ↗
48. 10.1039/D0ME00015A10.1039/D0ME00015A ↗
49. 10.1021/acs.macromol.1c0158710.1021/acs.macromol.1c01587 ↗
50. 10.1021/acs.macromol.2c0258510.1021/acs.macromol.2c02585 ↗
51. 10.1002/jbm.a.3509610.1002/jbm.a.35096 ↗
52. 10.1016/j.apmt.2020.10070010.1016/j.apmt.2020.100700 ↗
53. Braille Authority of North America Size and Spacing of Braille Characters, https://brailleauthority.org/size-and-spacing-braille-characters (accessed 2024–12–12).
54. 10.1002/anie.20180374710.1002/anie.201803747 ↗
55. 10.1021/ma501550b10.1021/ma501550b ↗
56. 10.1016/j.polymer.2018.10.02410.1016/j.polymer.2018.10.024 ↗
57. 10.1021/acsapm.8b0016510.1021/acsapm.8b00165 ↗
58. 10.1021/acscentsci.0c0092910.1021/acscentsci.0c00929 ↗
59. 10.1002/anie.20201652310.1002/anie.202016523 ↗
60. 10.1515/bpasts-2016-006810.1515/bpasts-2016-0068 ↗
61. 10.1111/j.2042-7158.1980.tb13090.x10.1111/j.2042-7158.1980.tb13090.x ↗